FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017588586> ?p ?o ?g. }

• W2017588586 abstract "New therapeutic indications based on the antiprogesterone action of RU 486 (Mifepristone) are emerging which require long term administration and raise the question of its safety because of the antiglucocorticoid action of the drug. A trial was designed to assess the antiglucocorticoid effect of RU 486, possible manifestations of peripheral cortisol deprivation, and the adrenocortical and corticotroph reserves. Ten normal male volunteers (aged 21-29 yr) were given RU 486 (200 mg/day) or placebo between 0800-0900 h for 8 consecutive days in a randomized, double blind, cross-over design, with a 1-month interval between the two periods. RU 486 induced overactivation of the pituitary-adrenal axis; baseline values (mean +/- SEM) before and at end of treatment were, respectively: 0800 h plasma cortisol, 147.3 +/- 15.5 and 257.6 +/- 8.8 ng/mL; 0800 h salivary cortisol, 5.8 +/- 1.2 and 15.2 +/- 0.8 ng/mL; nocturnal (2200-0800 h) urinary cortisol, 8.4 +/- 1.5 and 33.7 +/- 11.1 micrograms; and 0800 h plasma ACTH, 29.2 +/- 3.7 and 60.2 +/- 8.4 pg/mL. All of these variations were significantly different from those during placebo treatment (0.0001 < P < 0.03) and disappeared within 4 days after the end of treatment. A daily record of subjective clinical symptoms, body weight and temperature, blood pressure, and heart rate showed neither side-effects nor any significant variation during treatment. Blood electrolyte and eosinophil counts were unchanged; fasting blood glucose was slightly higher at the end of treatment (5.0 +/- 0.2 vs. 4.7 +/- 0.1 mmol/L; P = 0.04). The adrenocortical response to Cortrosyn (0.25 mg, im) was exaggerated during RU 486 treatment (P < 0.006): peak values before and at the end of treatment were, respectively: plasma cortisol, 272.5 +/- 15.2 and 347.1 +/- 20.6 ng/mL; and salivary cortisol, 17.0 +/- 2.2 and 31.1 +/- 3.1 ng/mL. Direct pituitary stimulation (100 micrograms ovine CRH, followed by 1 IU lysine vasopressin over 15 min) also induced exaggerated corticotroph and adrenocortical responses (P < 0.005); peak values before and at the end of treatment were, respectively: plasma ACTH, 147.7 +/- 24.6 and 254.0 +/- 41.3 pg/mL; and plasma cortisol, 231.6 +/- 7.3 and 319.2 +/- 12.3 ng/mL. These data show that 8-day treatment with 200 mg RU 486 daily induces a hormonally detectable antiglucocorticoid effect without clinical symptoms. This state results from reversible cortisol overproduction with preservation of adrenocortical and pituitary reserves.At Cochin Hospital in Paris, France, ten 21-29 year old normal male volunteers received either 200 mg RU-486 per day or a placebo for 8 consecutive days between 8:00 and 9:00 in the morning, then went through a 28-day washout period before receiving what they did not receive the first time for 8 days. The researchers wanted to examine the antiglucocorticoid effect of RU-486, any evidence of peripheral cortisol deprivation, and the adrenocortical and corticotroph reserves. An assessment of potential risk of longterm administration of RU-486 is needed to determine whether it can be used to treat chronic diseases (e.g., meningioma and breast cancer). RU-486 was responsible for overreaction of the pituitary-adrenal axis (8:00 am plasma cortisol, 147.3 ng/mL vs. 257.6 ng/mL; 8:00 am salivary cortisol, 5.8 ng/mL vs. 15.2 ng/mL; nocturnal urinary cortisol, 8.4 mcg vs. 33.7 mcg; and 8:00 am plasma adrenocorticotropic hormone [ACTH] 29.2 pg/mL vs. 60.2 pg/mL). All these changes differed significantly from those during placebo treatment (0.0001 p 0.03). These changes no longer existed 4 days after the end of treatment. The men kept a daily record of subjective clinical symptoms, body weight and temperature, blood pressure, and heart rate, which did not indicate any side effects or any considerable variation during treatment. RU-486 did not affect blood electrolyte and eosinophil counts. Blood glucose levels during fasting were somewhat higher at the end of treatment (p = 0.04). During RU-486 treatment, the adrenocortical response to 0.25 mg of intramuscularly injected Cortrosyn was amplified (peak values before and after, plasma cortisol, 272.5 ng/mL vs. 347.1 ng/mL; 17 ng/mL vs. 31.1 ng/mL) (p 0.006). Direct stimulation of the pituitary resulted in exaggerated corticotroph and adrenocortical responses (p 0.005). These findings showed that a daily dose of 200 mg RU-486 causes a hormonally detectable antiglucocorticoid effect but no clinical symptoms." @default.
• W2017588586 created "2016-06-24" @default.
• W2017588586 creator A5002734804 @default.
• W2017588586 creator A5005923141 @default.
• W2017588586 creator A5016095031 @default.
• W2017588586 creator A5016397577 @default.
• W2017588586 creator A5030387941 @default.
• W2017588586 creator A5046750707 @default.
• W2017588586 creator A5065783188 @default.
• W2017588586 creator A5085781691 @default.
• W2017588586 creator A5088656363 @default.
• W2017588586 date "1994-02-01" @default.
• W2017588586 modified "2023-10-12" @default.
• W2017588586 title "Administration of RU 486 for 8 days in normal volunteers: antiglucocorticoid effect with no evidence of peripheral cortisol deprivation." @default.
• W2017588586 cites W1967153353 @default.
• W2017588586 cites W1970539961 @default.
• W2017588586 cites W1974350281 @default.
• W2017588586 cites W1976834739 @default.
• W2017588586 cites W1984562516 @default.
• W2017588586 cites W2001099922 @default.
• W2017588586 cites W2006949121 @default.
• W2017588586 cites W2030764210 @default.
• W2017588586 cites W2032361181 @default.
• W2017588586 cites W2064035782 @default.
• W2017588586 cites W2072286966 @default.
• W2017588586 cites W2095590290 @default.
• W2017588586 cites W2100655603 @default.
• W2017588586 cites W2114712559 @default.
• W2017588586 cites W2118959975 @default.
• W2017588586 cites W2120423870 @default.
• W2017588586 cites W2131474586 @default.
• W2017588586 cites W2332316772 @default.
• W2017588586 cites W2339185636 @default.
• W2017588586 cites W2401336630 @default.
• W2017588586 cites W2412666741 @default.
• W2017588586 cites W587731629 @default.
• W2017588586 doi "https://doi.org/10.1210/jcem.78.2.8106625" @default.
• W2017588586 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8106625" @default.
• W2017588586 hasPublicationYear "1994" @default.
• W2017588586 type Work @default.
• W2017588586 sameAs 2017588586 @default.
• W2017588586 citedByCount "9" @default.
• W2017588586 countsByYear W20175885862016 @default.
• W2017588586 crossrefType "journal-article" @default.
• W2017588586 hasAuthorship W2017588586A5002734804 @default.
• W2017588586 hasAuthorship W2017588586A5005923141 @default.
• W2017588586 hasAuthorship W2017588586A5016095031 @default.
• W2017588586 hasAuthorship W2017588586A5016397577 @default.
• W2017588586 hasAuthorship W2017588586A5030387941 @default.
• W2017588586 hasAuthorship W2017588586A5046750707 @default.
• W2017588586 hasAuthorship W2017588586A5065783188 @default.
• W2017588586 hasAuthorship W2017588586A5085781691 @default.
• W2017588586 hasAuthorship W2017588586A5088656363 @default.
• W2017588586 hasConcept C126322002 @default.
• W2017588586 hasConcept C134018914 @default.
• W2017588586 hasConcept C142724271 @default.
• W2017588586 hasConcept C204787440 @default.
• W2017588586 hasConcept C27081682 @default.
• W2017588586 hasConcept C2778709874 @default.
• W2017588586 hasConcept C2778826759 @default.
• W2017588586 hasConcept C2779234561 @default.
• W2017588586 hasConcept C2780004078 @default.
• W2017588586 hasConcept C2780841215 @default.
• W2017588586 hasConcept C54355233 @default.
• W2017588586 hasConcept C59493245 @default.
• W2017588586 hasConcept C71924100 @default.
• W2017588586 hasConcept C86803240 @default.
• W2017588586 hasConceptScore W2017588586C126322002 @default.
• W2017588586 hasConceptScore W2017588586C134018914 @default.
• W2017588586 hasConceptScore W2017588586C142724271 @default.
• W2017588586 hasConceptScore W2017588586C204787440 @default.
• W2017588586 hasConceptScore W2017588586C27081682 @default.
• W2017588586 hasConceptScore W2017588586C2778709874 @default.
• W2017588586 hasConceptScore W2017588586C2778826759 @default.
• W2017588586 hasConceptScore W2017588586C2779234561 @default.
• W2017588586 hasConceptScore W2017588586C2780004078 @default.
• W2017588586 hasConceptScore W2017588586C2780841215 @default.
• W2017588586 hasConceptScore W2017588586C54355233 @default.
• W2017588586 hasConceptScore W2017588586C59493245 @default.
• W2017588586 hasConceptScore W2017588586C71924100 @default.
• W2017588586 hasConceptScore W2017588586C86803240 @default.
• W2017588586 hasLocation W20175885861 @default.
• W2017588586 hasLocation W20175885862 @default.
• W2017588586 hasOpenAccess W2017588586 @default.
• W2017588586 hasPrimaryLocation W20175885861 @default.
• W2017588586 hasRelatedWork W1992533206 @default.
• W2017588586 hasRelatedWork W2014418138 @default.
• W2017588586 hasRelatedWork W2015141992 @default.
• W2017588586 hasRelatedWork W2034277681 @default.
• W2017588586 hasRelatedWork W2035905240 @default.
• W2017588586 hasRelatedWork W2036237097 @default.
• W2017588586 hasRelatedWork W2078471485 @default.
• W2017588586 hasRelatedWork W2213857395 @default.
• W2017588586 hasRelatedWork W2355436147 @default.
• W2017588586 hasRelatedWork W2461219896 @default.
• W2017588586 isParatext "false" @default.
• W2017588586 isRetracted "false" @default.
• W2017588586 magId "2017588586" @default.
• W2017588586 workType "article" @default.